BC Week In Review | Mar 17, 2017
Company News

Shionogi, Duchesnay deal

Shionogi granted Duchesnay exclusive, U.S. and Canadian rights to develop and commercialize dyspareunia drug Osphena ospemifene. Shionogi will receive quarterly minimum payments for eight years and is eligible for undisclosed milestones. Osphena, a selective estrogen...
BC Week In Review | Dec 14, 2015
Clinical News

Ospemifene: Phase III started

Shionogi began a double-blind, placebo-controlled, U.S. Phase III trial to evaluate 60 mg oral Osphena once daily in about 600 patients. Osphena is approved in the U.S. to treat dyspareunia due to menopause. Shionogi has...
BioCentury | Jan 12, 2015
Finance

Buyside view XXIII: Milestones galore

Stephen Hansen, Associate Editor and Jennifer Rhodes, Staff Writer   Buyside view XXIII The maturation of the biotech sector over the past few years finds fund managers focusing on a slew of clinical milestones and...
BioCentury | Jan 13, 2014
Finance

Buyside View XXII: 'Grown up' means growth

Stephen Hansen Senior Writer  An increase in regulatory approvals and new breakthrough therapies has money managers buying into the concept that biotech has entered a new product cycle that provides a strong fundamental basis for...
BioCentury | Oct 14, 2013
Emerging Company Profile

Forendo: Fixing endometriosis

Forendo Pharma Oy is developing inhibitors of hydroxysteroid 17-beta dehydrogenase 1 to treat endometriosis without depleting circulating estrogen, thus avoiding side effects of available therapies. In endometriosis, tissue similar to endometrium in the uterus grows...
BC Week In Review | May 13, 2013
Company News

Shionogi sales and marketing update

Shionogi launched Osphena ospemifene in the U.S. to treat moderate to severe dyspareunia due to postmenopausal vulvovaginal atrophy. The wholesale acquisition cost is $158 for 30 once-daily tablets. FDA approved the selective estrogen receptor modulator...
BC Week In Review | Apr 1, 2013
Clinical News

Ospemifene regulatory update

Shionogi said EMA accepted for review an MAA for ospemifene to treat postmenopausal vulvovaginal atrophy. In February, FDA approved ospemifene as Osphena to treat moderate to severe dyspareunia due to postmenopausal vulvovaginal atrophy (see BioCentury,...
BioCentury | Apr 1, 2013
Finance

1Q Stock Wrap-Up: Out fast at opening bell

For the second year in a row, biotech put together a strong showing in the first quarter with all market segments gaining ground. The sector was led by mid-caps, which closed up 16%. Large caps...
BC Extra | Mar 28, 2013
Company News

EMA accepts ospemifene MAA for review

Shionogi & Co. Ltd. (Tokyo:4507; Osaka:4507) said EMA accepted for review an MAA for ospemifene to treat postmenopausal vulvovaginal atrophy. Shionogi has exclusive, worldwide rights, excluding undisclosed Baltic and Nordic territories, to the selective estrogen...
BC Week In Review | Mar 4, 2013
Clinical News

Osphena ospemifene regulatory update

FDA approved an NDA from Shionogi for Osphena ospemifene to treat moderate to severe dyspareunia due to postmenopausal vulvovaginal atrophy. The drug's label includes a boxed warning that it can cause endometrial thickening and an...
Items per page:
1 - 10 of 39